Alvotech (ALVO) Q3 2025 earnings summary

Executive summary

• Achieved strong revenue growth driven by global biosimilar launches, with a 127% CAGR from 2021 to 2024 and projected 94% CAGR through 2025.

• Q3 2025 results aligned with expectations, with product revenues and margins affected by order timing, portfolio mix, and facility investments.

• Entered new markets, holding leading or top-three positions in key biosimilar segments in the U.S., Europe, and Canada.

• Achieved a profit of $136.5 million for the nine months ended 30 September 2025, reversing a loss of $164.9 million in the prior year period.

• Addressed FDA Complete Response Letter (CRL) for Simponi biosimilar, with manufacturing improvements underway and anticipated U.S. approval in H1 2026.

Financial highlights

• Q3 2025 total revenues reached $114 million, up 11% year-over-year; last twelve months run-rate at $571 million.

• Nine-month 2025 revenues reached $420 million, up 24% year-on-year, with gross margin at 59% and adjusted EBITDA of $68 million (16% margin).

• Product and service revenue rose to $237.4 million from $128.0 million year-over-year.

• Cash balance at end of September was $43 million, reflecting inventory build-up, CAPEX, and M&A outflows.

• Revised full-year 2025 guidance: $570–$600 million in revenues and $130–$150 million adjusted EBITDA.

Outlook and guidance

• Expecting strong Q4 2025 due to new launches and licensing revenues, with 19% revenue and 30% EBITDA growth targeted at guidance midpoint.

• Full-year 2025 revenue guidance revised to $570–600 million (from $600–700 million); Adj. EBITDA revised to $130–150 million (from $200–280 million).

• Licensing agreements for pipeline assets deferred to 2026; management expects top-line and EBITDA growth in 2026.

• Strategic focus on pipeline advancement, global launches, cost optimization, and margin expansion over the next 18 months.

• Significant improvement in profitability and cash flow positions the company for future growth.